SalterAFoxRJNewsomeSD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol2021; 78(6): 699–708.
2.
Simpson-YapSDe BrouwerEKalincikT, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology2021; 97(19): e1870–e1885.
3.
SpelmanTForsbergLMcKayK, et al. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish Multiple Sclerosis Registry. Mult Scler2022; 28(7): 1051–1059.
4.
PortaccioEFondericoMHemmerB, et al. Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler J2021; 28: 132–138.
5.
Cobo-CalvoAZabalzaARíoJ, et al. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. J Neurol2022; 269: 1773.
6.
RolfesLPawlitzkiMPfeufferS, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm2021; 8(5): e1035.
7.
Van LieropZYGJTooropAAvan BallegoijWJC, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler2022; 28(7): 1121–1125.
8.
GarjaniAPatelSBharkhadaD, et al. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Mult Scler Relat Disord2021; 57: 103458.
9.
BoeschotenREBraamseAMJBeekmanATF, et al. Prevalence of depression and anxiety in multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci2017; 372: 331–341.
10.
UhrLMateenFJ.COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey. Mult Scler2022; 28(7): 1072–1080.
11.
SormaniMPSchiavettiILandiD, et al. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Mult Scler J2022; 28(7): 1034–1040.
12.
LouapreCIbrahimMMaillartE, et al. Anti-CD20 therapies decrease humoral immune response to sars-cov-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry2021; 93: 24–31.
13.
ZabalzaAArrambideGTaglianiP, et al. Humoral and cellular responses to SARS-CoV-2 in convalescent COVID-19 patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2022; 9(2): e1143.
14.
SormaniMPIngleseMSchiavettiI, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. Ebiomedicine2021; 72: 103581.
15.
CohenJABermelRAGrossmanCI, et al. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Mult Scler2022; 28(7): 1131–1137.
16.
TortorellaCAielloAGasperiniC, et al. Humoral- and T-cell–specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology2022; 98: 13108.
17.
ZabalzaAArrambideGOtero-RomeroS, et al. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with Multiple Sclerosis and other autoimmune diseases?Mult Scler J2022; 28(7): 1138–1145.
18.
GeorgievaZGDӧffingerRKumararatneD, et al. Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients. Mult Scler2022; 28(7): 1126–1130.
19.
RommerPSBstehGBergerT, et al. SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action. Mult Scler2022; 28(1): 165–167.
20.
JanuelEDe SezeJVermerschP, et al. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Mult Scler2022; 28(7): 1155–1159.
21.
SchiavettiICordioliCStromilloML, et al. Breakthrough SARS-CoV-2 infections in MS patients on disease modifying therapies. Medrxiv. Epub ahead of print 31 January 2022. DOI: 10.1101/2022.01.22.22269630.
22.
DamsLKraemerMBeckerJ.MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination. Mult Scler2022; 28(7): 1159–1162.
23.
RinaldiVBellucciGRomanoA, et al. ADEM after ChAdOx1 nCoV-19 vaccine: A case report. Mult Scler2022; 28(7): 1151–1154.
24.
MocciaM. Demyelinating disorders following COVID-19 vaccination. Mult Scler J2021; 362: 1046903.
25.
WrightS.MOG antibody–associated longitudinal extensive myelitis after Oxford-Astra Zeneca’s COVID-19 vaccination. Mult Scler J2022; 28(7): 1163.
